XML 56 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Inventory [1] $ 1,456,597 $ 756,134
Severance expenses 120,753 145,979
Warranty expenses 1,173 8,540
Accounts receivable 91,719  
Right-of-use assets 250,000  
Derivative liability   768,249
Increase in additional paid-in capital   2,505,723
Decrease in accumulated deficit   $ 2,505,723
Fourth Quarter of 2018 [Member]    
Inventory 700,000  
Inception Through December 2004 [Member]    
Cumulative research and development $ 93,300  
[1] Management evaluates whether inventory reserve for slow-moving or obsolete items is required. To date, as a result of low volume of revenues generated from the sales of the GlucoTrack® model DF-F glucose monitoring device the Group has recorded reserves with respect to its inventory in the amount of approximately US$ 1,457 thousand. (of which an amount of US$ 700 thousand was recognized in the fourth quarter of 2018)